Psychiatr. pro Praxi, 2003; 6: 267

Hormonální substituční terapie a demence

MUDr. Martin Vališ1, MUDr. Jiří Masopust2, MUDr. Ing. Aleš Urban2
1 Neurologická klinika LF UK a FN v Hradci Králové
2 Psychiatrická klinika LF UK a FN Hradec Králové

Published: December 31, 2003  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vališ M, Masopust J, Urban A. Hormonální substituční terapie a demence. Psychiatr. praxi. 2003;4(6):267.

Riziko rozvoje Alzheimerovy choroby se zdá být u postmenopauzálních žen vyšší než u mužů. Mnohé studie naznačují, že estrogeny hrají významnou roli v etiopatogenezi Alzheimerovy demence (AD). Jedním z faktorů, který je spojován s AD, je pokles ovariální hormonální funkce u postmenopauzálních žen. Opakovaně bylo popsáno zlepšení kognitivních funkcí a snížení incidence tohoto onemocnění u postmenopauzálních žen s estrogenní substitucí (1, 5, 15). Dosud byl přijímán názor, že postmenopauzální substituce má pozitivní protektivní účinek na rozvoj demence. Jedním z dalších důvodů k indikaci hormonální substituční terapie (HRT) u žen by tedy bylo možné snížení rizika vzniku demence. Vysoké dávky HRT vedly k signifikantnímu zlepšení bdělosti a paměti (2). Podávání estrogenů ale vnímáme jako možnou prevenci AD, ne však její léčbu.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Birge SJ. The role of estrogen in the treatment of Alzheimer´s disease. Neurology 1997; 48 (Suppl 7): 36-41. Go to original source... Go to PubMed...
    2. De Souza EB. Corticotropin releasing factor receptor,physiology, pharmacology, biochemistry and role in central nervous system and immune disorders. Psychoneuroendocrinol 1995; 20: 789-819. Go to original source... Go to PubMed...
    3. Francis PT, Cross AJ, Bownen MD. Neurotransmitters and neuropeptides. In: Terry RD, Katzman R, Bick KL eds. Alzheimer´s disease. New York: Raven Press 1994; 247-261.
    4. Grossman RI, Yousem DM. Neuroradiology. St.Louis: Mosby 1994; 232-235.
    5. Jirák R. Farmakoterapie kognitivních funkcí u demencí se zaměřením na Alzheimerovu chorobu - současné možnosti a perspektivy. Remedia 1997; 7: 92-96.
    6. Jorm AF, Korten AE, Henderson AS. The prevalence of dementia: a quantitative integration of the literature. Acta Psych Scand 1987; 76: 465-479. Go to original source... Go to PubMed...
    7. Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer´s disease: a randomised controlled trial. Alzheimer´s Disease Cooperative Study. JAMA 2000; 286: 1007-1015. Go to original source... Go to PubMed...
    8. Ott A, Breteler MMB, Van Harskamp F et al. Prevalence of Alzheimer's disease and vaskular dementia, associaation with education. The Rotterdam study. BMJ 1995; 310: 970-973. Go to original source... Go to PubMed...
    9. Pike CJ. Estrogen modulates neuronal Bcl-xL expression and beta apoptosis amyloid-induced, relevance to Alzheimer´s disease. Psychiatry Res 1999; 85: 71-80. Go to PubMed...
    10. Rapp SR, Espeland MA, Shumaker SA et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: The Women´s Health Initiative Memory Study: a randomised controlled trial. JAMA 2003; 289: 2663-2672. Go to original source... Go to PubMed...
    11. Rossouw JE, Anderosn GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal esults From the Women´s Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333. Go to original source... Go to PubMed...
    12. Shumaker SA, Legault C, Thal L, et al. WHIMS Investigators: Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women´s Health Initiative Memory study: a randomised controlled trial. JAMA 2003; 289: 2651-2662. Go to original source... Go to PubMed...
    13. Singh VK. Neuroautoimmunity pathogenetic implication for Alzheimer´s disease. Gerontology 1997; 43: 79-94. Go to original source... Go to PubMed...
    14. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women´s Health Initiative: a randomized trial. JAMA 2003; 289: 2673-2684. Go to original source... Go to PubMed...
    15. Whalley LJ, Struth MA. The prevention of cognitive decline in late life. Alzheimer´s Research 1997; 11 (Suppl 4): 35-38.

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.